Prot #D8540C00001: A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/R

Project: Research project

Project Details

StatusFinished
Effective start/end date3/7/18 → 3/7/23

Funding

  • Covance Inc. (Prot #D8540C00001)
  • MedImmune, LLC (Prot #D8540C00001)